Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-07-30FDA Approved: TRAZODONE HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for trazodone hydrochloride as a generic product under an ANDA filed by Sun Pharmaceutical Industrie…
-
FDA approval · 2013-07-26FDA Approved: DOXEPIN — Original Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s generic doxepin as an original ANDA, providing a generic option for this antidepressant.
-
FDA approval · 2013-07-25FDA Approved: FETZIMA — Original Application (Allergan, Inc.)
FDA approved FETZIMA (levomilnacipran hydrochloride) as a new prescription antidepressant for the treatment of major depressive disorder fol…
-
FDA approval · 2013-06-28FDA Approved: PAROXETINE — Original Application (Padagis US LLC)
FDA approved a paroxetine product from Padagis US LLC under an original application.
-
FDA approval · 2013-06-12FDA Approved: ESCITALOPRAM ORAL SOLUTION — Original Application (Chartwell RX, LLC)
FDA approved a generic escitalopram oral solution from Chartwell RX, LLC under an Original Application (ANDA). It is indicated for major dep…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2013-06-10FDA Approved: ESCITALOPRAM — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s supplemental application for escitalopram (generic) under ANDA202389. This approval marks a supplement…
-
FDA approval · 2013-06-08FDA Approved: VIIBRYD — Supplemental Application (Allergan, Inc.)
The FDA approved Allergan's supplemental application for Viibryd (vilazodone hydrochloride). The action pertains to a supplemental submissio…
-
FDA approval · 2013-05-31FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for escitalopram oxalate from Rising Pharma Holdings, Inc., approving a generic version under the AN…
-
FDA approval · 2013-05-31FDA Approved: ESCITALOPRAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved the supplemental application for escitalopram oxalate by Aurobindo Pharma Limited, enabling continued generic production and di…
-
FDA approval · 2013-05-21FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for escitalopram oxalate from Macleods Pharmaceuticals Limited, allowing the generic product to be m…
-
FDA approval · 2013-05-20FDA Approved: ESCITALOPRAM — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for ESCITALOPRAM (escitalopram oxalate) from Sun Pharmaceutical Industries, Inc., approving this gen…
-
FDA approval · 2013-04-30FDA Approved: SEROQUEL — Supplemental Application (H2-Pharma, LLC)
The FDA approved a supplemental NDA for SEROQUEL (quetiapine) filed by H2-Pharma, LLC.
-
FDA approval · 2013-04-30FDA Approved: CITALOPRAM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Citalopram hydrobromide from Aurobindo Pharma Limited.
-
FDA approval · 2013-04-30FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)
The FDA approved a supplemental application for SEROQUEL XR (quetiapine) submitted by AstraZeneca, resulting in changes to the product label…
-
FDA approval · 2013-04-30FDA Approved: CITALOPRAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for the generic antidepressant citalopram from Mylan Pharmaceuticals Inc. This action represents…
-
FDA approval · 2013-04-26FDA Approved: CITALOPRAM — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for citalopram submitted by Cipla USA Inc., indicating approval of a supplemental marketing authoriz…
-
FDA approval · 2013-04-22FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Teva Pharmaceuticals USA, Inc. to market the olanzapine and fluoxetine combination (OLANZAPINE A…
-
FDA approval · 2013-04-19FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
FDA approved a supplemental application for Pristiq Extended-Release (desvenlafaxine succinate), authorizing the extended-release formulatio…
-
FDA approval · 2013-03-25FDA Approved: OLANZAPINE AND FLUOXETINE — Original Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's olanzapine and fluoxetine combination as an original ANDA generic product for depressive episodes in bipolar I disorder …
-
FDA approval · 2013-03-19FDA Approved: WELLBUTRIN SR — Supplemental Application (GlaxoSmithKline LLC)
FDA approved a supplemental application for Wellbutrin SR (bupropion hydrochloride) from GlaxoSmithKline LLC.
-
FDA approval · 2013-03-14FDA Approved: OLANZAPINE AND FLUOXETINE — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for a generic olanzapine and fluoxetine combination submitted by Par Health USA, LLC. The product is…
-
FDA approval · 2013-03-04FDA Approved: DESVENLAFAXINE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved desvenlafaxine (brand Pristiq) from Sun Pharmaceutical Industries, Inc. in an original NDA for the treatment of major depressiv…
-
FDA approval · 2013-02-14FDA Approved: PRISTIQ EXTENDED-RELEASE — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application to authorize the extended-release formulation of desvenlafaxine succinate (Pristiq Extended-Rele…
-
FDA approval · 2013-02-12FDA Approved: QUETIAPINE — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' generic quetiapine fumarate under an original ANDA, making a generic version of quetiapine available.
-
FDA approval · 2013-02-01FDA Approved: ZOLOFT — Supplemental Application (ROERIG)
FDA approved a supplemental application for ZOLOFT (sertraline hydrochloride) submitted by ROERIG.